Molecular prognostic prediction in liver cirrhosis

Nicolas Goossens, Shigeki Nakagawa, Yujin Hoshida

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The natural history of cirrhosis varies and therefore prognostic prediction is critical given the sizable patient population. A variety of clinical prognostic indicators have been developed and enable patient risk stratification although their performance is somewhat limited especially within relatively earlier stage of disease. Molecular prognostic indicators are expected to refine the prediction, and potentially link a subset of patients with molecular targeted interventions that counteract poor prognosis. Here we overview clinical and molecular prognostic indicators in the literature, and discuss critical issues to successfully define, evaluate, and deploy prognostic indicators as clinical scores or tests. The use of liver biopsy has been diminishing due to sampling variability on fibrosis assessment and emergence of imaging-or lab testbased fibrosis assessment methods. However, recent rapid developments of genomics technologies and selective molecular targeted agents has highlighted the need for biopsy tissue specimen to explore and establish molecular information-guided personalized/stratified clinical care, and eventually achieve precision medicine.

Original languageEnglish (US)
Pages (from-to)10262-10273
Number of pages12
JournalWorld Journal of Gastroenterology
Volume21
Issue number36
DOIs
StatePublished - Sep 28 2015
Externally publishedYes

Fingerprint

Liver Cirrhosis
Fibrosis
Biopsy
Precision Medicine
Genomics
Technology
Liver
Population

Keywords

  • Biomarker
  • Cirrhosis
  • Gene expression
  • Hepatocellular carcinoma
  • Prognosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Molecular prognostic prediction in liver cirrhosis. / Goossens, Nicolas; Nakagawa, Shigeki; Hoshida, Yujin.

In: World Journal of Gastroenterology, Vol. 21, No. 36, 28.09.2015, p. 10262-10273.

Research output: Contribution to journalReview article

Goossens, Nicolas ; Nakagawa, Shigeki ; Hoshida, Yujin. / Molecular prognostic prediction in liver cirrhosis. In: World Journal of Gastroenterology. 2015 ; Vol. 21, No. 36. pp. 10262-10273.
@article{95e3ae3ef8b5400b9b8e972ba167ee70,
title = "Molecular prognostic prediction in liver cirrhosis",
abstract = "The natural history of cirrhosis varies and therefore prognostic prediction is critical given the sizable patient population. A variety of clinical prognostic indicators have been developed and enable patient risk stratification although their performance is somewhat limited especially within relatively earlier stage of disease. Molecular prognostic indicators are expected to refine the prediction, and potentially link a subset of patients with molecular targeted interventions that counteract poor prognosis. Here we overview clinical and molecular prognostic indicators in the literature, and discuss critical issues to successfully define, evaluate, and deploy prognostic indicators as clinical scores or tests. The use of liver biopsy has been diminishing due to sampling variability on fibrosis assessment and emergence of imaging-or lab testbased fibrosis assessment methods. However, recent rapid developments of genomics technologies and selective molecular targeted agents has highlighted the need for biopsy tissue specimen to explore and establish molecular information-guided personalized/stratified clinical care, and eventually achieve precision medicine.",
keywords = "Biomarker, Cirrhosis, Gene expression, Hepatocellular carcinoma, Prognosis",
author = "Nicolas Goossens and Shigeki Nakagawa and Yujin Hoshida",
year = "2015",
month = "9",
day = "28",
doi = "10.3748/wjg.v21.i36.10262",
language = "English (US)",
volume = "21",
pages = "10262--10273",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "36",

}

TY - JOUR

T1 - Molecular prognostic prediction in liver cirrhosis

AU - Goossens, Nicolas

AU - Nakagawa, Shigeki

AU - Hoshida, Yujin

PY - 2015/9/28

Y1 - 2015/9/28

N2 - The natural history of cirrhosis varies and therefore prognostic prediction is critical given the sizable patient population. A variety of clinical prognostic indicators have been developed and enable patient risk stratification although their performance is somewhat limited especially within relatively earlier stage of disease. Molecular prognostic indicators are expected to refine the prediction, and potentially link a subset of patients with molecular targeted interventions that counteract poor prognosis. Here we overview clinical and molecular prognostic indicators in the literature, and discuss critical issues to successfully define, evaluate, and deploy prognostic indicators as clinical scores or tests. The use of liver biopsy has been diminishing due to sampling variability on fibrosis assessment and emergence of imaging-or lab testbased fibrosis assessment methods. However, recent rapid developments of genomics technologies and selective molecular targeted agents has highlighted the need for biopsy tissue specimen to explore and establish molecular information-guided personalized/stratified clinical care, and eventually achieve precision medicine.

AB - The natural history of cirrhosis varies and therefore prognostic prediction is critical given the sizable patient population. A variety of clinical prognostic indicators have been developed and enable patient risk stratification although their performance is somewhat limited especially within relatively earlier stage of disease. Molecular prognostic indicators are expected to refine the prediction, and potentially link a subset of patients with molecular targeted interventions that counteract poor prognosis. Here we overview clinical and molecular prognostic indicators in the literature, and discuss critical issues to successfully define, evaluate, and deploy prognostic indicators as clinical scores or tests. The use of liver biopsy has been diminishing due to sampling variability on fibrosis assessment and emergence of imaging-or lab testbased fibrosis assessment methods. However, recent rapid developments of genomics technologies and selective molecular targeted agents has highlighted the need for biopsy tissue specimen to explore and establish molecular information-guided personalized/stratified clinical care, and eventually achieve precision medicine.

KW - Biomarker

KW - Cirrhosis

KW - Gene expression

KW - Hepatocellular carcinoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84942362017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942362017&partnerID=8YFLogxK

U2 - 10.3748/wjg.v21.i36.10262

DO - 10.3748/wjg.v21.i36.10262

M3 - Review article

C2 - 26420954

AN - SCOPUS:84942362017

VL - 21

SP - 10262

EP - 10273

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 36

ER -